Policy

Latest News


CME Content


The US Surgeon General, Vice Admiral Jerome Adams, MD, and other officials urged for greater uptake of FDA-approved treatments for coronavirus disease 2019 (COVID-19) in an effort to slow the surge of cases requiring hospitalization. However, logistic, monetary, and efficacy concerns may have drastically limited the amount of biologic treatments actually administered to patients.

The coronavirus disease 2019 (COVID-19) pandemic has had a disproportionate impact on racial and ethnic minorities in America. MJH Life Sciences™ will host a free webinar to explore potential solutions.

Bringing together genetic work with social determinants of health can improve understanding of factors associated with ESKD disparities, said Adriana Hung, MD, MPH, associate professor of medicine at Vanderbilt University, and Bryce Rowan, a statistical genetic analyst.

A funding dispute over how to account for a Veterans Affairs (VA) health care program is stalling deal to fund the government for another year; the Supreme Court rules in a case involving states and pharmacy benefit managers (PBMs); the antiepileptic drug ezogabine lowered the pathologic excitability of cortical and spinal motor neuron cells, which have a role in amyotrophic lateral sclerosis (ALS).

In the span of a few weeks, Pfizer, Moderna, and AstraZeneca all announced positive results from their respective coronavirus disease 2019 (COVID-19) vaccine trials, with Pfizer submitting to FDA for an emergency use authorization (EUA) on November 20.

Brand Logo

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo